Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer AbbVie’s ELAHERE has been approved in Russia for the treatment of epithelial ovarian, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 13 August 2026: Celltrion’s CT-P73 receives US FDA FTD for recurrent/metastatic Cervical cancer Celltrion announced that the U.S. FDA has granted Fast Track designation to CT-P73, a Tissue Factor-targeted ADC, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 10 August 2026: ITM receives Complete Response Letter for ITM-11 ITM announced that the U.S. FDA issued a Complete Response Letter for the NDA of 177Lu-edotreotide, an investigational targeted radiotherapeutic […]
Weekly Digest – August 2026 Weekly Digest – August 2026 13 August 2026: Asieris received FDA IND approval for APL‑2501 for the treatment of advanced Solid tumors Asieris Pharmaceuticals announced that the U.S. FDA has cleared the IND application for […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in the EU as […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease Novartis announced that the U.S. FDA has approved Pluvicto in combination with […]
Weekly Digest – August 2026 Weekly Digest – August 2026 04 August 2026: U.S. Food and Drug Administration grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253 Multitude Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy Designation to AMT-253, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 05 August 2026: Multitude Therapeutics’ AMT-676 receives Breakthrough Therapy Designation from China’s CDE Multitude Therapeutics’ CDH17-targeted ADC AMT-676 has been granted Breakthrough Therapy Designation by China’s CDE for the treatment […]
Weekly Digest – August 2026 Weekly Digest – August 2026 03 August 2026: TQB2102 receives BTD from the CDE for patients with unresectable or metastatic HER2-low Breast cancer Sino Biopharmaceutical’s next-generation HER2 bispecific ADC TQB2102 has received its third Breakthrough […]
Weekly Digest – August 2026 Weekly Digest – August 2026 03 August 2026: U.S. FDA grants Orphan Drug Designation to Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan for the treatment of Neuroendocrine Carcinomas Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan has received […]
